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Abstract  
Objectives: Aberrant methylation of promoter CpG islands (CGIs) of tumour suppressor 
genes is a common epigenetic mechanism underlying cancer pathogenesis. The 
methylation patterns of thymic tumours have not been studied in detail since such tumours 
are rare. Herein, we sought to identify genes that could serve as epigenetic targets for 
thymic neuroendocrine tumour (NET) therapy.  
Materials and Methods: Genome-wide screening for aberrantly methylated CGIs was 
performed in three NET samples, seven thymic carcinoma (TC) samples, and eight type-B3 
thymoma samples. The methylation status of thymic epithelial tumours (TETs) samples was 
validated by pyrosequencing in a larger cohort. The expression status was analysed by 
quantitative polymerase chain reaction (PCR) and immunohistochemistry. 
Results: We identified a CGI on a novel gene, RASSF1A, which was strongly 
hypermethylated in NET, but not in thymic carcinoma or B3 thymoma. RASSF1A was 
identified as a candidate gene statistically and bibliographically, as it showed frequent CGI 
hypermethylation in NET by genome-wide screening. Pyrosequencing confirmed significant 
hypermethylation of a RASSF1A CGI in NET. Low-grade NET tissue was more strongly 
methylated than high-grade NET. Quantitative PCR and immunohistochemical staining 
revealed that RASSF1A mRNA and protein expression levels were negatively regulated by 
DNA methylation. 
Conclusions: RASSF1A is a tumour suppressor gene epigenetically dysregulated in NET. 
Aberrant methylation of RASSF1A has been reported in various tumours, but this is the first 
report of RASSF1A hypermethylation in TETs. RASSF1A may represent an epigenetic 
therapeutic target in thymic NET. 
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1. Introduction 
 The 4th edition of the World Health Organization (WHO) Classification of tumours of the 
lung, pleura, thymus, and heart classified typical and atypical carcinoids as low-grade and 
intermediate-grade thymic neuroendocrine tumours (NETs), respectively, and distinguished 
them from high-grade neuroendocrine carcinomas (NECs), which, in turn, comprised 
large-cell neuroendocrine carcinomas and small-cell carcinomas [1]. The overall survival 
rates of NET and thymic carcinoma (TC) patients are lower than that of thymoma patients 
[2,3]. However, the biological features of thymic epithelial tumours (TETs), including NETs, 
have not been elucidated because these are rare tumours, preventing the development of 
effective therapeutic strategy, though the TET staging system had been established based 
on the survival and recurrence rates by the International Association for the Study of Lung 
Cancer and the International Thymic Malignancies Interest Group [4,5,6,7]. It is therefore 
necessary to identify biomarkers that could be used for the early detection of these cancers 
and for the development of novel targeted therapies to improve the survival rate． 
Aberrant methylation of promoter CpG islands (CGIs) of tumour suppressor genes has 
been established as a common epigenetic mechanism underlying the pathogenesis of 
various cancers in humans, including lung adenocarcinoma [8,9,10]. However, there have 
been no reports about the DNA methylation pattern in thymic epithelial tumours (TETs) 
because this type of cancer, especially NET, is relatively rare. In the present study, we 
performed a systematic, genome-wide screening of aberrantly methylated CGIs in NET, TC, 
and B3 thymoma samples to identify commonly dysregulated genes. In addition, we aimed 
to identify novel genes that could serve as epigenetic targets for NET therapy. 
 
2. Methods 
2.1. Primary tissue sample collection 
In total, 51 thymic tumour samples and 10 paired normal tissues were obtained from 
patients with histologically proven TET, who underwent surgery at the Tokushima University 
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Hospital (Tokushima, Japan) between 1990 and 2016. The breakdown of 51 thymic tumour 
samples by diagnosis was as follows: NET, 11 samples; TC, 11 samples; type B3 thymoma, 
9 samples; type B2 thymoma, 7 samples; type B1 thymoma, 5 samples; type AB thymoma, 
5 samples; and type A thymoma, 3 samples. DNA methylation genome-wide screening was 
carried out with a HumanMethylation450K array. Pyrosequencing-based methylation 
analysis validated the methylation status of the candidate gene. Expression was analysed 
by quantitative PCR and immunohistochemistry (Table 1, Supplementary Table 1).  
Tumours were snap-frozen and stored at −80 °C until required for DNA and RNA analysis. 
Tumour specimens were characterised according to Masaoka-Koga [11] and WHO 
classifications [12]. Diagnosis was verified by histopathology.  
This study was performed in accordance with the principles outlined in the Declaration of 
Helsinki. Following the approval of all aspects of these studies by the local ethics committee 
(Tokushima University Hospital, approval numbers 2205-1, 2228), formal written consent 
was obtained from all patients.  
 
2.2. DNA and RNA preparation and bisulphite conversion of genomic DNA  
DNA and RNA were extracted using standard methods. Bisulphite conversion of DNA 
was conducted using an EZ DNA Methylation Gold kit (Zymo Research, Irvine, CA, USA). 
 
2.3. Global methylation analysis 
HumanMethylation450K BeadChip (Illumina, Santa Clara, CA, USA) analysis was 
performed according to the manufacturer's instructions. The default settings of the 
GenomeStudio software DNA methylation module (Illumina) were applied to calculate the 
methylation levels of CpG sites as β-values (β = intensitymethylated/intensitymethylated + 
unmethylated). The data were further normalised using the peak correction algorithm embedded 
in the Illumina Methylation Analyzer (IMA) R package [8]. To identify CGIs differentially 
methylated in NET and TC samples in the discovery set, median-averaged β-differences in 
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CGI-based regions were calculated based on a matrix of β-differences, in which β-values of 
TC samples were subtracted from those of NET samples. The statistical significance of 
these differences was evaluated using Welch’s t-test in IMA. Multiple testing corrections 
were performed using the Benjamini–Hochberg approach, with significantly differential 
methylation defined as a false discovery rate (FDR)-adjusted P-value < 0.05. The following 
criteria were used for differentially methylated CGIs: β-difference > 0.5 and FDR-adjusted 
P-value < 0.05. Methylation data for the discovery cohort were deposited in the Gene 
Ontology Database under accession number GSE94769. 
 
2.4. Bisulphite pyrosequencing  
Bisulphite-treated genomic DNA was amplified using a set of primers designed with the 
PyroMark Assay Design software (version 2.0.01.15; Qiagen, Valencia, CA, USA; 
Supplementary Table 4). PCR product pyrosequencing and methylation quantification were 
performed with a PyroMark 24 Pyrosequencing System, version 2.0.6 (Qiagen) with 
sequencing primers designed according to the manufacturer’s instructions.  
 
2.5. Quantitative PCR  
Quantitative PCR (qPCR) was performed using a TaqMan gene expression assay kit 
(Supplementary Table 4) according to the manufacturer’s instructions. GAPDH mRNA levels 
were used as the internal controls for normalization.  
 
2.6. Immunohistochemical staining  
Paraffin-embedded sections (thickness, 4 µm) were heated in a microwave oven for 20 
min for antigen retrieval. A CSA II kit (DAKO Japan, Tokyo, Japan) and a primary antibody 
against RASSF1A (Supplementary Table 4) were used according to the manufacturer’s 
instructions [9]. The intensity and expansion of RASSF1A stain in the NET, TC, and B3 
samples were scored. We defined stain score as the sum of the intensity and expansion 
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scores. A stain score of ≤2 indicated inhibition of protein expression. Immunohistochemical 
(IHC) data scoring was performed independently by two different researchers. 
 
2.7. Statistical analysis 
Results are expressed as the mean ± standard deviation. Welch’s t-test or unpaired 
Student’s t-test was used for comparisons between two groups. Mann–Whitney U test was 
used for comparisons between non-paired samples, when data were not normally 
distributed. The relation between continuous variables was investigated by calculating the 
Pearson’s correlation coefficient. Differences were assessed by using two-sided tests and 
were considered significant at a P-value of <0.05. Statistical analyses were performed using 
R 3.2.2 (R Project for Statistical Computing, Vienna, Austria). 
 
3. Results 
3.1. Screening of aberrantly methylated CGIs in tumour samples  
We initially screened three NET samples, seven TC samples, and eight B3 thymoma 
samples obtained from freshly frozen specimens (Table 1, Supplementary Table 1) with an 
Illumina HumanMethylation450K BeadChip to identify differentially methylated CGIs in a 
genome-wide manner. A volcano plot showed that, in NET samples, the number of 
significantly different and hypermethylated CGIs was much larger than the number of 
hypomethylated CGIs, which was in contrast to the results obtained for TC or B3 thymoma 
samples (Fig. 1A, B). Thirty-five CGIs were identified as differentially hypermethylated in the 
NET samples in relation to the TC samples (FDR < 0.05 and β difference [NET – TC] > 0.5). 
Furthermore, 39 CGIs were identified as differentially hypermethylated in the NET samples 
compared with the B3 thymoma samples using the same statistical criteria. RASSF1A was 
among the top 15 differentially methylated genes in the NET samples compared with the TC 
(Supplementary Table 2) and B3 thymoma (Supplementary Table 3) samples. In addition, 
we identified ten genes as commonly hypermethylated in NET (Fig. 1C). RASSF1A was one 
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of the most significant hypermethylated genes in the NET samples.  
 
3.2. CGI methylation status of the RASSF1A promoter in TETs 
Using the methylation array data of 22 TET samples (three NET samples, seven TC 
samples, eight B3 thymoma samples, three thymoma A samples, and one normal thymus 
tissue sample), we analysed the methylation status of CpG sites within RASSF1A [10]. CpG 
sites within the CGI exhibited low levels of methylation in samples from TC, thymomas, and 
normal thymic tissue. In contrast, significantly higher methylation levels were detected in the 
NET samples in all CpG sites (Fig. 2A). 
Quantitative pyrosequencing analysis of five target CpG sites within the RASSF1A CGI 
revealed very low methylation levels in all five CpG sites in the TC, thymoma, and normal 
thymic tissue samples, whereas the NET samples exhibited high levels of DNA methylation 
(Fig. 2B). Therefore, the DNA methylation levels in the NET samples in all five RASSF1A 
CpG sites were significantly different from those in samples from other TETs or from normal 
thymic tissue. 
Pyrosequencing demonstrated that low-grade and intermediate-grade NETs, known as 
typical and atypical carcinoids, respectively, had significantly (P = 1.53 × 10-9) 
hypermethylated CpG sites on RASSF1A promoter region cg21554552 (II) compared to 
their methylation level in NECs (Fig. 3A). 
 
3.3. Expression of RASSF1A in TETs 
QPCR analysis showed that the RASSF1A mRNA expression level was lower in NETs 
than in other TETs and normal thymic tissue (Fig. 4A). There was a negative correlation 
between the extent of methylation of CpG sites and RASSF1A expression levels in 
cg21554552 (II) in TETs and normal thymic tissue (Fig. 4B). Apparently, DNA methylation of 
the RASSF1A promoter region regulated RASSF1A mRNA expression. To evaluate the 
RASSF1A protein expression level in TET, IHC staining was performed (Fig. 5A). 
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Cytoplasmic RASSF1A staining was observed in tumour cells of TC and B3 thymoma, 
whereas almost no RASSF1A staining was observed in NET cells. IHC analysis of scores of 
staining intensity and expansion of RASSF1A-specific stain showed that RASSF1A protein 
expression was significantly (P = 0.02) inhibited in NETs.  
 
4. Discussion 
In this present study, we performed genome-wide screening of various thymic tumours, 
including NETs, to identify novel genes that could be epigenetic therapeutic targets. We 
focused on the methylation status and expression level of RASSF1A, one of the ten 
candidate genes that exhibited significantly higher methylation levels in NET samples than 
in TC or B3 thymoma specimens. The methylation analysis revealed that the promoter 
region of RASSF1A was significantly methylated in NETs compared to in TC and/or B3 
thymoma. The expression levels of RASSF1A mRNA and protein were inhibited in NETs 
compared to in other TETs and/or normal thymus tissues. DNA methylation of the RASSF1A 
promoter region regulated the expression of RASSF1A in thymic NETs. 
RASSF1 is a member of the RASSF family (RASSF1–8). This gene gives rise to eight 
different isoforms due to alternative splicing and alternative promoter usage [14]. In contrast 
to RAF and phosphatidylinositol 3-kinase, which are RAS effectors that specifically bind the 
GTP-bound form of RAS and control proliferation and survival, RASSF proteins are known 
as tumour suppressors because they induce cell cycle arrest, mitotic arrest, and apoptosis 
[14,15,16]. Loss of RASSF1A expression is largely attributed to promoter hypermethylation, 
as somatic mutations of RASSF1A are uncommon, although several polymorphisms have 
been detected [17]. Frequently, high level of DNA methylation of the promoter region and 
low expression of RASSF1A have been associated with negative prognosis of 
neuroendocrine tumours of other organs such as the pancreas, gastrointestinal tract, 
bronchi, or lungs [15,16,18,19,20]. However, to the best of our knowledge, the present study 
is the first to report the inverse relationship between the DNA methylation status of 
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RASSF1A and its expression level in thymic tumours, including NETs. Our results suggest 
that RASSF1A might be a novel epigenetic target of cancer therapy.  
Besides RASSF1A, our study identified several other genes that could be candidate 
molecular targets for the epigenetic modification therapy of thymic NET (Fig. 1C). The 
protein product of SKI represses TGF-β-induced epithelial-mesenchymal transition and 
invasion by inhibiting SMAD-dependent signalling in non-small cell lung cancer [21]. The 
transmembrane 106A gene (TMEM106A) is a novel tumour suppressor gene silenced by 
DNA methylation in gastric cancer [22]. Palladin, encoded by PALLD, regulates the ability of 
cancer cells to become invasive and metastatic [23]. The latent transforming growth factor 
β-binding protein gene (LTBP4) is downregulated in adenocarcinomas and squamous cell 
carcinomas in oesophageal cancer [24]. Gene fusions of THAP4 with VAV1 (VAV1-THAP4) 
generate recurrent in-frame deletions (VAV1 Δ778-786) by a focal deletion-driven alternative 
splicing mechanism in peripheral T-cell lymphomas [25]. GNG8 is involved in the 
WNT/β-catenin- and G protein-coupled receptor signalling pathways in chronic lymphocytic 
leukaemia and small lymphocytic lymphoma [26]. TMEM37 is likely to be methylated as a 
consequence of rat mammary carcinogenesis, but it is not expressed in normal mammary 
glands [27]. SRRM3 may be involved in breast cancer progression mediated by RING1 and 
YY1-binding protein [28]. Therefore, SKI, TMEM106A, PALLD, LTBP4, THAP4, GNG8, and 
SRRM3 may be candidate genes for epigenetic target therapy, in addition to RASSF1A.  
Nowadays, it is possible to demethylate targeted CpG sites in regulatory regions using 
fusion proteins containing the dCas9-peptide repeat and the scFv-TET1 catalytic domain 
[29]. This new technology has applications in the development of epigenetic target therapy 
for various cancers. Therefore, it is necessary to identify target CpG sites and/or 
epigenetically controlled regions on driver genes. The results of this study might aid the 
development of targeted therapy for thymic NETs.  
There are several limitations to this study. First, type B1 and B2 thymomas were 
excluded from our methylation and expression analysis, because these tumours were 
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infiltrated by large quantities of lymphocytes, and we could not selectively analyse epithelial 
tumour cells. Second, apart from RASSF1A, we could not survey the other candidate genes 
in detail. We focused on RASSF1A in this study as this gene has been reported to be 
hypermethylated in NETs of other organs such as pancreas, gastrointestinal tract, bronchi, 
and lungs [15,16,18,19,20]. Third, only a small cohort of NET samples was used for the 
genome-wide analysis. This small sample size might not have been sufficient to detect all 
epigenetically controlled candidate genes. In addition, it was unclear whether the expression 
of RASSF1A could play role in the prognosis in thymic NETs. Finally, we did not perform 
functional assays for RASSF1A in the thymus. 
In conclusion, the expression of RASSF1A, a known tumour-suppressor gene, was found 
to be epigenetically controlled in thymic NETs as well as NETs of other tissues. Our results 
suggest that RASSF1A is a candidate gene for epigenetic target therapy.  
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Figure captions 
Fig. 1. RASSF1A is a candidate gene with selective hypermethylation of CpG islands 
(CGIs) in thymic neuroendocrine tumours (NETs). 
A. Volcano plot of the differential CGI methylation profiles of three NET and seven thymic 
carcinoma samples. The x-axis indicates the average β-value difference (methylation 
level). The y-axis indicates the –log10 value of the adjusted Welch’s test P-value for 
each CGI. The arrow indicates the CGI around RASSF1A. 
B. Volcano plot of the differential CGI methylation profiles of three NET and eight B3s 
thymoma samples. The x-axis indicates the average β-value difference (methylation 
level). The y-axis indicates the –log10 value of the adjusted Welch’s test P-value for 
each CGI. The arrow indicates the CGI around RASSF1A. 
C. The top 15 genes, whose methylation status was significantly different in NET vs. TC 
samples and in NET vs. B3 thymoma samples according to the following criteria: false 
discovery rate (FDR) < 0.05; β difference (NET – TC) > 0.5. The methylation status of 
ten genes was significantly different in NET samples in comparison with TC and B3 
thymoma samples. 
 
Fig. 2. Methylation status of RASSF1A in thymic epithelial tumours (TETs). 
A. A schematic diagram of the RASSF1A structure and CpG sites around exon 1α. 
Average β-values indicating the methylation level of each CpG site are indicated. The 
array-based methylation experiment involved three NET samples, seven TC samples, 
eight B3 thymoma samples, three thymoma A samples, and one normal thymic tissue 
sample. The CpG sites around exon 1α on the promoter region targeted by 
pyrosequencing are shown as I–V. 
B. Average DNA methylation rates of five target sites indicated in A obtained by 
quantitative pyrosequencing of TETs, including NETs.  
 
17 
 
Fig. 3. DNA methylation levels in thymic tumours of different grades.  
DNA methylation levels of cg21554552 (target II in Fig. 2A, B) were analysed by 
quantitative pyrosequencing in low-grade and intermediate-grade NETs as well as in 
high-grade neuroendocrine carcinomas. The dotted line indicates a methylation level of 
0.3. Samples were defined as being hypermethylated at cg21554552 if the methylation 
rate was above 0.3. 
 
Fig. 4. RASSF1A mRNA expression level in TET.  
A. Boxplot of the relative RASSF1A mRNA expression levels (fold change) in TET samples, 
as determined by quantitative polymerase chain reaction (qPCR). Data were normalised 
to GAPDH mRNA levels and are expressed as the mean ± standard deviation of 
experiments performed in triplicate. 
B. Correlation between the methylation rate of the CpG site cg21554552 (II) and RASSF1A 
expression level. The x-axis indicates the methylation level determined by 
pyrosequencing. The y-axis indicates the RASSF1A mRNA expression level determined 
by qPCR and normalised to that of GAPDH.  
 
Figure 5. RASSF1A protein expression level in TET. 
A. Representative images of immunohistochemical staining for RASSF1A in NET, TC, and 
B3 thymoma samples. Scale bars, 200 μm. 
B. Scores of the intensity and expansion of RASSF1A-specific stain in NET, TC, and B3 
thymoma samples. Staining score = intensity score + expansion score. Protein 
expression was considered to be inhibited if the stain score was ≤2.  
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Table 1. Clinicopathological characteristics of patients with thymic epithelial tumor used screening genome-wide methylation assay
group histology age gender (M:F) with MG Masaoka classification
NET (n=3)
low-intermediate-grade NET 58.7±5.6 (51-64) 2:1 0 1 n=1
3 n=1
4b n=1
TC (n=7)
squamous cell carcinoma 59.1±5.2 (51-69) 3:4 0 2 n=3
3 n=1
4a n=1
4b n=1
B3 (n=8)
type B3 thymoma 57.9±17.2 (28-75) 2:6 2 1 n=2
2 n=1
3 n=3
4a n=2
Table S1. Clinicopathological characteristics of patients with thymic epithelial tumor used methylation and expression analysis in this study
sample
ID
group
ID biospecimen age gender MG
Masaoka
classification histology　/　WHO classification
methylation screening
(Human methylation 450K)
methylation
(pyrosequence)
expression
(RT-PCR)
expression
(immunohistochemistry)
1 NET frozen 51 F - 3 carcinoid / low-inetmediate-grade NET ○ ○ ○ ○
2 TC frozen 55 M - 2 squamous cell carcinoma ○ ○ ○ ○
3 TC frozen 51 F - 2 squamous cell carcinoma ○ ○
4 A frozen 50 F - 1 thymoma type A ○ ○ ○
5 TC frozen 60 M - 2 squamous cell carcinoma ○ ○ ○ ○
6 TC frozen 58 F - 4 squamous cell carcinoma ○ ○ ○ ○
7 TC frozen 69 F - 4b squamous cell carcinoma ○ ○ ○ ○
8 TC frozen 60 F - 4a squamous cell carcinoma ○ ○
9 B3 frozen 66 M - 1 thymoma type B3 ○ ○ ○ ○
10 B3 frozen 28 F + 4a thymoma type B3 ○ ○ ○ ○
11 B3 frozen 75 F - 1 thymoma type B3 ○ ○ ○ ○
12 B3 frozen 64 M - 2 thymoma type B3 ○ ○ ○
13 NET frozen 61 M - 1 carcinoid / low-inetmediate-grade NET ○ ○ ○ ○
14 B3 frozen 36 M + 4a thymoma type B3 ○ ○ ○
15 B2 frozen 50 F + 3 thymoma type B2 ○
16 TC frozen 61 M - 3 squamous cell carcinoma ○ ○ ○ ○
17 NET frozen 64 M - 4b atypical carcinoid / inetmediate-grade NET ○ ○ ○ ○
18 B3 frozen 47 M - 3 thymoma type B3 ○ ○ ○ ○
19 A frozen 62 M - 1 thymoma type A ○ ○ ○
20 B3 frozen 75 M - 3 thymoma type B3 ○ ○ ○ ○
22 NET frozen 67 F - 4b small cell carcinoma / high-grade NEC ○ ○ ○
23 B3 frozen 72 M - 3 thymoma type B3 ○ ○ ○ ○
24 A frozen 80 F - 1 thymoma type A ○ ○ ○
25 TC frozen 61 F - 2 squamous cell carcinoma ○ ○ ○
27 B2 frozen 74 F - 2 thymoma type B2 ○ ○
28 B2 frozen 65 F - 2 thymoma type B2 ○ ○
31 B2 frozen 75 F - 2 thymoma type B2 ○
33 TC frozen 68 F - 2 squamous cell carcinoma ○ ○ ○
34 B3 frozen 68 F + 2 thymoma type B3 ○ ○ ○
35 TC frozen 69 M - 2 squamous cell carcinoma ○ ○
36 B1 frozen 65 F - 1 thymoma type B1 ○
37 TC frozen 48 F - 3 squamous cell carcinoma ○ ○
38 B2 frozen 40 F - 2 thymoma type B2 ○ ○
39 B2 frozen 52 F + 2 thymoma type B2 ○ ○
40 B2 frozen 60 F - 1 thymoma type B2 ○ ○
41 B1 frozen 84 M - 2 thymoma type B1 ○
42 B1 frozen 51 F + 2 thymoma type B1 ○
43 B1 frozen 71 F - 2 thymoma type B1 ○
44 B1 frozen 72 F - 1 thymoma type B1 ○ ○
45 AB frozen 67 F + 1 thymoma type AB ○
46 AB frozen 58 M - 2 thymoma type AB ○
47 AB frozen 65 F - 2 thymoma type AB ○ ○
48 AB frozen 56 F + 2 thymoma type AB ○
49 AB frozen 74 F - 1 thymoma type AB ○
50 NET frozen 68 M - 2 typical cartinoid / low-grade NET ○ ○ ○
51 NET FFPE 53 M - unknown cartinoid ○ ○
52 NET FFPE 61 M - unknown cartinoid ○ ○
53 NET FFPE 71 M - unknown cartinoid ○ ○
54 NET FFPE 45 F - unknown atypical carcinoid / inetmediate-grade NET ○ ○
55 NET FFPE 70 F - unknown high-grade NEC ○ ○
56 NET FFPE 49 M - unknown high-grade NEC ○ ○
57 Non-tumor frozen 58 F - - normal thymus (case6) ○
58 Non-tumor frozen 80 F - - normal thymus (case24) ○
59 Non-tumor frozen 61 F - - normal thymus (case25) ○ ○
60 Non-tumor frozen 74 F - - normal thymus (case27) ○ ○
61 Non-tumor frozen 65 F - - normal thymus (case28) ○ ○
62 Non-tumor frozen 40 M + - normal thymus (case30) ○ ○
63 Non-tumor frozen 69 M - - normal thymus (case35) ○
64 Non-tumor frozen 48 F - - normal thymus (case37) ○
66 Non-tumor frozen 68 M - - normal thymus (case50) ○
65 Non-tumor FFPE 49 M - - normal thymus (case55) ○
patient Sample for analysis
Rank CpG island Adjusted p-value beta.Difference Gene name Location of CpG island
1 chr1:2222198-2222569 4.81E-10 0.6983 SKI Gene body
2 chr19:11533198-11533619 9.62E-10 0.6095 CCDC151 Gene body
3 chr17:41363727-41364273 7.59E-08 0.7567 TMEM106A Exon 1
4 chr12:57635240-57635572 1.51E-05 0.5032 NDUFA4L2 upstream
5 chr4:169753048-169754535 1.51E-05 0.5823 PALLD Gene body
6 chr7:75896510-75896944 1.51E-05 0.7600 SRRM3 Gene body
7 chr19:41115445-41115767 1.04E-04 0.5224 LTBP4 Gene body
8 chr19:38885233-38885505 1.56E-04 0.6203 SPRED3 Gene body
9 chr3:50377803-50378540 1.60E-04 0.5323 RASSF1 Exon 1
10 chr12:132690339-132690571 2.84E-04 0.6605 GALNT9 Exon 1
11 chr2:242549373-242549995 2.84E-04 0.5121 THAP4 Gene body
12 chr19:47139337-47139547 2.95E-04 0.5784 GNG8 upstream
13 chr2:120190030-120190308 2.95E-04 0.5812 TMEM37 Gene body
14 chr16:374732-375328 3.09E-04 0.6649 AXIN1 Gene body
15 chr11:119613005-119613521 3.40E-04 0.5138 RGL3 upstream
Table S2.  Top of 15 CpG islands significantly hypermethylated in NET compared to squamous cell carcinomas
Methyaltion status of CpG island CpG island-related RefSeq gene
Rank CpG island Adjusted p-value beta.Difference Gene name Location of CpG island
1 chr1:2222198-2222569 3.84E-12 0.6974 SKI Gene body
2 chr17:41363727-41364273 1.78E-09 0.7593 TMEM106A Exon 1
3 chr19:42386865-42387485 7.38E-08 0.5052 ARHGEF1 Gene body
4 chr19:47507306-47507692 2.36E-07 0.5583 GRLF1 upstream
5 chr2:120190030-120190308 5.68E-07 0.6231 TMEM37 Gene body
6 chr7:75896510-75896944 8.45E-07 0.7492 SRRM3 Gene body
7 chr18:35104533-35104942 2.39E-06 0.5470 BRUNOL4 Gene body
8 chr19:41115445-41115767 2.52E-06 0.5350 LTBP4 Gene body
9 chr7:75889086-75889345 2.75E-06 0.7061 SRRM3 Gene body
10 chr4:169753048-169754535 3.83E-06 0.5706 PALLD Exon 1
11 chr2:242549373-242549995 9.01E-06 0.5419 THAP4 Gene body
12 chr9:139580969-139582615 9.55E-06 0.5153 AGPAT2 Exon 1
13 chr19:11533198-11533619 1.23E-05 0.5828 CCDC151 Body
14 chr3:50377803-50378540 1.24E-05 0.6013 RASSF1 Exon 1
15 chr19:47139337-47139547 1.34E-05 0.5205 GNG8 upstream
Table S3. Top of 15 CpG islands significantly hypermethylated in NETs compared to type B3 thymomas
Methyaltion status of CpG island CpG island-related RefSeq gene
Gene/primer name Sequence/ID
Forward 5'-ATTTGGGTGTAGGGATTGTG-3'
Reverse Biotin-5'-AACTAACCTCCAAAAACACAAAT-3'
Sequence TGTAGGGATTGTGGG 
RASSF1 FAM Hs00296057_m1
GAPDH FAM Hs02758991_g1
ID dilution Vender
Immunohistochemistry for RASSF1
ab23950 1:500 Abcam plc, Cambridge, UK
* TaqMan gene expression assay were produced by Thermo Fisher SCIENTIFIC(Yokohama, Japan)
TaqMan gene expression assay*
Pyrosequencing for RASSF1
Table S4. List of primer sets used in TaqMan  and antibody in immunochemistry.
